๐๏ธ Verified NIH Record โข Updated 2026-04-30
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease (NCT04624490)
๐ข Recruiting Phase1 ๐ Investigational Drug / Biologic Sponsor: Mario Castro, MD, MPH
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
Who can join: Review the eligibility criteria below.
Location: University of Kansas Medical Center โ Kansas City, Kansas
Age range: 3 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- University of Kansas Medical Center โ Kansas City, Kansas
๐ Contact the Study Coordinator
Phone: (913) 945-9399
Email: chernandez@kumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype โ Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma โ Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma โ Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma โ San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma โ Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study โ La Jolla, California
Explore by condition: All Asthma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.